0001213900-19-000014.txt : 20190102 0001213900-19-000014.hdr.sgml : 20190102 20190102070035 ACCESSION NUMBER: 0001213900-19-000014 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190102 FILED AS OF DATE: 20190102 DATE AS OF CHANGE: 20190102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Holdings Ltd. CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38370 FILM NUMBER: 19500057 BUSINESS ADDRESS: STREET 1: 3 SAPIR ST. STREET 2: WEIZMANN SCIENCE PARK, P.O.B. 4132 CITY: NESS-ZIONA STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 3 SAPIR ST. STREET 2: WEIZMANN SCIENCE PARK, P.O.B. 4132 CITY: NESS-ZIONA STATE: L3 ZIP: 74140 6-K 1 f6k010219_collplanthold.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2019

Commission File Number 001-38370

CollPlant Holdings Ltd.

(Exact name of registrant as specified in its charter)

3 Sapir Street, Weizmann Science Park

Ness Ziona 74140, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

CollPlant Holdings Ltd. (the “Company”) recently formed a committee to search for a U.S.-based chairperson of the Board of Directors. As previously reported, the Company and U.S.-based United Therapeutics announced the entry into a License, Development and Commercialization Agreement for 3D bioprinted lung transplants, and the Company is seeking to further advance its 3D bioprinting business in the U.S. with various companies that are evaluating CollPlant’s rhCollagen based BioInk for the bioprinting of organs and tissues.

On January 1, 2019, David Tsur notified the Company of his resignation as the Chairman and as a member of the Board of Directors, effective March 31, 2019, or earlier if a new Chairperson is appointed, to pursue other opportunities.

The Board of Directors thanks Mr. Tsur for his contribution as Chairman and wishes him success in his future endeavors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT HOLDINGS LTD.

Date: January 2, 2019	By:	/s/ Eran Rotem
		Name: Eran Rotem
		Title: Deputy CEO and Chief Financial Officer